Cargando…

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farren, Timothy W., Sadanand, Kaushik S., Agrawal, Samir G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744938/ https://www.ncbi.nlm.nih.gov/pubmed/33344247 http://dx.doi.org/10.3389/fonc.2020.597730

Ejemplares similares

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
por: Farren, T W, et al.
Publicado: (2015)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia
por: Lee, Jae Wook, et al.
Publicado: (2022)

The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
por: Fisher, A., et al.
Publicado: (2023)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
por: Ghia, Emanuela M., et al.
Publicado: (2022)

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
por: Kamel, Azza M., et al.
Publicado: (2022)

Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
por: Bozorgmehr, Najmeh, et al.
Publicado: (2021)

Increased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia
por: Wang, Hua‐Qing, et al.
Publicado: (2019)

STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia
por: Liu, Feng-Ting, et al.
Publicado: (2016)

Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms
por: El- Neanaey, Wafaa Ahmed, et al.
Publicado: (2020)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia
por: Wang, Yu, et al.
Publicado: (2021)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia
por: Moffitt, Andrea B, et al.
Publicado: (2020)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Ror2 Signaling and Its Relevance in Breast Cancer Progression
por: Bayerlová, Michaela, et al.
Publicado: (2017)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia
por: Assumpção, Juliana Godoy, et al.
Publicado: (2013)

Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
por: Ringelstein-Harlev, Shimrit, et al.
Publicado: (2014)

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
por: Johnston, Andrew D., et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
por: Rosati, Emanuela, et al.
Publicado: (2018)

Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia
por: Isabelle, Colleen, et al.
Publicado: (2022)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study
por: Arthur, Cecilia, et al.
Publicado: (2022)

Treatment of Minimal Residual Disease in Breast Cancer: A Longitudinal Case Study
por: Murray, Nigel P
Publicado: (2017)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice
por: Galimberti, Sara, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7bql5panad9oocgv1v8dpl3vfs